ストックスクリーナーアプリを入手
0.8313
2.30%
-0.0196
プレマーケット:
.84
0.0087
+1.05%
Inflarx N V (IFRX) 最新ニュース
Is InflaRx N.V. (IF0) stock among top earnings playsPortfolio Update Summary & Growth Oriented Trading Recommendations - mfd.ru
Treasury Yields: Is InflaRx NV forming bullish engulfing patternsEarnings Risk Summary & Smart Investment Allocation Tips - baoquankhu1.vn
InflaRx N.V. (NASDAQ:IFRX) Receives $7.50 Consensus PT from Analysts - Defense World
Here's Why We're A Bit Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Situation - Sahm
InflaRx N.V. (NASDAQ:IFRX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
InflaRx launches public offering of shares and warrants - MSN
InflaRx (NASDAQ:IFRX) Trading 10.4% HigherStill a Buy? - MarketBeat
Here's Why InflaRx (NASDAQ:IFRX) Must Use Its Cash Wisely - Yahoo Finance
History Review: Is InflaRx NV showing insider buyingWeekly Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
Tech Rally: Can InflaRx NV sustain earnings growth2025 EndofYear Setup & Daily Technical Stock Forecast Reports - baoquankhu1.vn
InflaRx Announces Participation in February Investor Conferences - marketscreener.com
Can InflaRx N.V. deliver consistent dividendsTrade Risk Summary & Weekly Market Pulse Alerts - mfd.ru
InflaRx NV Explodes After FDA Greenlight: Is IFRX the Biotech Underdog You’re Sleeping On? - AD HOC NEWS
Buyback Watch: Is InflaRx NV showing insider buyingJuly 2025 Levels & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Can InflaRx N.V. (IF0) stock sustain margin levelsMarket Performance Recap & Technical Analysis for Trade Confirmation - bollywoodhelpline.com
Is InflaRx N.V. stock positioned for digital transformationMarket Movers & Safe Entry Point Identification - bollywoodhelpline.com
Meme Stocks: Can InflaRx NV deliver consistent dividends2025 Pullback Review & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Bank Watch: Is Montauk Renewables Inc a potential multi baggerWatch List & Low Drawdown Momentum Ideas - baoquankhu1.vn
Biotech Update: IFRX, ABCL, RLYB Stand Out as Significant Gainers After Hours - Intellectia AI
Bull Run: Why InflaRx N.V. (IF0) stock could rally stronglyJuly 2025 Levels & Weekly High Potential Stock Alerts - Bộ Nội Vụ
InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Pullback Watch: Will InflaRx NV stock recover faster than market2025 Key Highlights & Daily Profit Maximizing Tips - Bộ Nội Vụ
Is InflaRx N.V. stock a top pick in earnings season2025 Fundamental Recap & Intraday High Probability Setup Alerts - Улправда
Why InflaRx N.V. stock remains on buy listsWeekly Investment Recap & Reliable Breakout Stock Forecasts - Улправда
How InflaRx N.V. stock valuations compare to rivalsInflation Watch & Technical Pattern Recognition Alerts - Улправда
InflaRx Cuts Workforce and Refocuses Strategy on Lead Drug Izicopan to Extend Cash Runway to 2027 - TipRanks
Will InflaRx N.V. stock recover faster than market2025 Top Gainers & Advanced Swing Trade Entry Alerts - Улправда
Why is InflaRx Stock Falling Today?InflaRx (NASDAQ:IFRX) - Benzinga
InflaRx stock falls after announcing restructuring and pipeline prioritization By Investing.com - Investing.com India
InflaRx stock falls after announcing restructuring and pipeline prioritization - Investing.com
InflaRx to prioritize izicopan development, cuts workforce by 30% - Investing.com South Africa
InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation - GlobeNewswire
What analysts say about InflaRx NV IF0 stockPrice Support Zones & Follow Top Performers in the Community - earlytimes.in
InflaRx Reopens Case For Axed Phase 3 Drug For Rare Skin Disorder - Sahm
Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? - RTTNews
InflaRx (IFRX) stock: biotech battleground after a volatile quarter and shifting expectations - AD HOC NEWS
InflaRx NV Is Exploding: Hidden Biotech Underdog or Just Another Hype Trap? - AD HOC NEWS
Raymond James reiterates Outperform rating on Inflarx stock at $9 target - Investing.com
Short Interest in InflaRx N.V. (NASDAQ:IFRX) Increases By 26.7% - MarketBeat
InflaRx reports potential efficacy signals in failed PG drug trial By Investing.com - Investing.com Nigeria
InflaRx (IFRX) Shares Mixed Results from Vilobelimab Phase 3 Trial in Ulcerative PG - parameter.io
InflaRx reveals phase 3 post‑hoc efficacy signals for vilobelimab in pyoderma gangrenosum after trial halt - MSN
Momentum Shift: Is InflaRx NV stock a top pick in earnings seasonLong Setup & Growth-Oriented Investment Plans - Bộ Nội Vụ
InflaRx (NASDAQ:IFRX) Receives Buy Rating from HC Wainwright - MarketBeat
InflaRx Reports Efficacy Signals In Terminated Phase 3 Study Of Vilobelimab In Pyoderma Gangrenosum - Nasdaq
InflaRx Shares In-Dept Analysis About Vilobelimab, Stock Down In Pre-Market - Nasdaq
InflaRx reports potential efficacy signals in failed PG drug trial - Investing.com
InflaRx N.V. Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum - marketscreener.com
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):